secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2023-07-31T23:59:59+00:00
Accession:  0001193125-23-198589
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA agrees to SPA for Spero's Phase 3 tebipenem HBr trial; $30M milestone due from GSK
--------------------------------------------------------------------------------

- FDA granted Special Protocol Assessment (SPA) for pivotal Phase 3 PIVOT-PO trial of oral tebipenem HBr vs IV imipenem in cUTI/acute pyelonephritis.
- Positive results from PIVOT-PO plus prior studies could support FDA approval for a limited use indication.
- Spero to receive $30M development milestone from GSK upon invoicing; additional milestones up to $495M plus tiered royalties.
- PIVOT-PO first patient first visit expected in Q4 2023; trial uses 10% non-inferiority margin per FDA guidance.
- SPR720 Phase 2 enrollment continues; top-line data now expected in H2 2024 (slower than prior guidance).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312523198589/0001193125-23-198589-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312523198589/d518650d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-198589

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer